Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of FCN-437c in Subjects With Impaired Liver Function
NCT06620731Phase 1Completed
- Sponsor
- Jinzhou Ahon Pharmaceutical Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ongiciclib in breast cancer and solid tumor (3 arms), sponsored by Jinzhou Ahon Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started Sep 2023; status: completed.
02
Drugs
ongiciclib
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT06620731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620731.